Dermira’s lebrikizumab Fast Track’d for atopic dermatitis; shares up 12%

Dermira (DERM +12.3%) is up on modestly higher volume in reaction to Fast Track status in the U.S. for IL-13 inhibitor lebrikizumab for the treatment of atopic dermatitis.

Two Phase 3 studies, ADvocate 1 and ADvocate 2, are in process.

Fast Track provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

https://seekingalpha.com/news/3525169-dermiras-lebrikizumab-fast-trackd-for-atopic-dermatitis-shares-up-12